Gland Pharma Q3 Result: Net up 34% at Rs 273 cr
The Hyderabad-based drug maker had reported a profit after tax (PAT) of Rs 204 crore in the corresponding period of the previous fiscal.
Gland Pharma on Friday posted a 34 per cent increase in its consolidated profit after tax at Rs 273 crore for the third quarter ended December 31, 2021, riding on robust sales across various markets.
The Hyderabad-based drug maker had reported a profit after tax (PAT) of Rs 204 crore in the corresponding period of the previous fiscal.
See Zee Business Live TV Streaming Below:
Revenue from operations rose to Rs 1,063 crore in the October-December period of the current fiscal as against Rs 859 crore in the same period of 2020-21 fiscal, Gland Pharma said in a regulatory filing.
"While our key market US grew by 23 per cent during the quarter, our focus on geographical diversification is showing robust results with a y-o-y growth of 88 per cent in the Rest of the World markets during the quarter," Gland Pharma MD & CEO Srinivas Sadu noted.
In alignment with strategic priorities, the company has completed four complex injectable filings and a total of 18 ANDA filings during the quarter, he added.
"We are starting this new year with renewed optimism to accomplish many more milestones," Sadu stated.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Top 7 SBI Mutual Funds With Best SIP Returns in 15 Years: Rs 8,333 monthly SIP investment in No 1 fund is now worth Rs 1,06,51,565; here's what others have given
Power of Compounding: How long will it take your Rs 2,00,000 investment to turn into Rs 8,00,000? Know through this investment rule
Home Loan EMI vs SIP Calculator: Should you go for Rs 65 lakh, 25-year home loan or start SIP investment of same worth? Know maths of both
09:11 PM IST